Global Competition Review: No Harboured Feelings: The Tipline for 26 February 2020

February 26, 2020

O’Melveny secured a win for Par Pharmaceutical’s in an antitrust suit filed against it by Fresenius Kabi, this article reported. Global Competition Review noted the antitrust claim alleged Par violated state and federal antitrust laws by delaying the market entry of the generic drug vasopressin. However, Judge Susan Wigenton granted Par’s motion for summary judgment, holding that the company’s patent breaks the chain of causation for showing antitrust injury.